These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 21294770)

  • 21. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
    Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
    Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.
    Bergenstal RM; Tamborlane WV; Ahmann A; Buse JB; Dailey G; Davis SN; Joyce C; Peoples T; Perkins BA; Welsh JB; Willi SM; Wood MA;
    N Engl J Med; 2010 Jul; 363(4):311-20. PubMed ID: 20587585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study.
    Rosenlund S; Hansen TW; Andersen S; Rossing P
    Diabet Med; 2015 Nov; 32(11):1445-52. PubMed ID: 26331364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Satisfaction with the Use of Different Technologies for Insulin Delivery and Glucose Monitoring Among Adults with Long-Standing Type 1 Diabetes and Problematic Hypoglycemia: 2-Year Follow-Up in the HypoCOMPaSS Randomized Clinical Trial.
    Speight J; Holmes-Truscott E; Little SA; Leelarathna L; Walkinshaw E; Tan HK; Bowes A; Kerr D; Flanagan D; Heller SR; Evans ML; Shaw JAM
    Diabetes Technol Ther; 2019 Nov; 21(11):619-626. PubMed ID: 31335201
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoglycemia and blood glucose fluctuations in the application of a sensor-augmented insulin pump.
    Luo P; Cheng Q; Chen B; Li Y; Wu J; Zhang X; Jiao X; Zhao J; Lv X
    Diabetes Technol Ther; 2013 Dec; 15(12):984-9. PubMed ID: 24004044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes.
    Willi SM; Planton J; Egede L; Schwarz S
    J Pediatr; 2003 Dec; 143(6):796-801. PubMed ID: 14657831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children.
    Zucchini S; Scipione M; Balsamo C; Maltoni G; Rollo A; Molinari E; Mangoni L; Cicognani A
    Diabetes Technol Ther; 2011 Dec; 13(12):1187-93. PubMed ID: 21854193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
    Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Schwarz E; Ólafsdóttir AF; Frid A; Wedel H; Ahlén E; Nyström T; Hellman J
    JAMA; 2017 Jan; 317(4):379-387. PubMed ID: 28118454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
    Breton MD; Kanapka LG; Beck RW; Ekhlaspour L; Forlenza GP; Cengiz E; Schoelwer M; Ruedy KJ; Jost E; Carria L; Emory E; Hsu LJ; Oliveri M; Kollman CC; Dokken BB; Weinzimer SA; DeBoer MD; Buckingham BA; Cherñavvsky D; Wadwa RP;
    N Engl J Med; 2020 Aug; 383(9):836-845. PubMed ID: 32846062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
    Pickup JC; Sutton AJ
    Diabet Med; 2008 Jul; 25(7):765-74. PubMed ID: 18644063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes.
    Müller N; Kloos C; Frank T; Ristow M; Wolf G; Müller UA
    Diabet Med; 2011 Feb; 28(2):223-6. PubMed ID: 21219434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.